Introduction {#s1}
============

Circadian clocks have been defined as endogenous oscillators that synchronize daily both physiological and behavioral rhythms with local time cues ([@B1], [@B2]). In mammals, this evolutionary adaptation provides a survival advantage to anticipate environmental changes and allowing them to modify their daily rhythms in the most efficient way to meet these environmental changes ([@B1], [@B3], [@B4]).

Consequences of modern lifestyle as sleep deprivation, shift work time schedule, altered mealtime or excessive artificial light exposure at night promote metabolic imbalances that can alter the circadian system. Interestingly, dysfunction of the molecular clock is linked to uncontrolled cell proliferation in human cancer ([@B5]--[@B7]). Changes in circadian clock increase risk of different cancers in endocrine tissues which require daily proliferation to carry out their activity. Thus, a considerable part of endocrine signals are clock-controlled ([@B8]). The dysregulation mechanisms of the circadian clock genes is greatly affected by polymorphic variants of circadian clock-related genes, which can raise human cancer risk through different physiological systems ([@B9]).

This mini-review focused on the role of single polymorphisms of circadian clock genes that similarly to environmental factors might increase the risk of developing human endocrine cancers.

Circadian Clock Mechanism, Clock Genes, and Cancer {#s2}
==================================================

The circadian clock regulates both physiology and behavior according to the daily cycle of light and dark. In mammals, it is hierarchically organized and integrates the master clock, which is located in the suprachiasmatic nucleus (SCN) within the hypothalamus, and the peripheral clocks as well, ubiquitously found virtually in all peripheral tissues and cells ([@B10]). SCN clock is constantly coupled to environmental cues, mainly photoperiod, through the photic signals from the retina ([@B11]), daily rhythms in temperature, diet and social phenomena through a complex downstream neurohumoral pathways. Oscillators located in brain nuclei and peripheral tissues are also connected by SCN clock ([@B12]).

Circadian rhythms are controlled by circadian pathway genes. The molecular circadian clock is originated by a transcriptional/translational loop of circadian clock genes with autoregulatory feedback. The primary loop involves the genes *CLOCK, BMAL1* (also known as *ARNTL1), PER1--3*, and *CRY1-2*. During the day, the complex integrated by CLOCK and BMAL1 stimulates the expression of negative regulators period genes (*PER1--3*) and cryptochrome genes (*CRY1-2*). Heterodimers constituted by PER and CRY operate as co-repressors, binding to the CLOCK-BMAL1 complex and inhibiting *CRY* and *PER* gene transcription induced by CLOCK-BMAL1. Furthermore, in the dark phase, *CRY* and *PER* expression decrease to the CRY-PER repressor complex. This leads to a new cycle of the transcription activation of the *CLOCK-BMAL1* complex, which completes the basic auto regulatory loop ([@B8], [@B13]). Otherwise, different modulators display fine tuning of output signals in molecular clock.

Currently, several core circadian genes, also known as circadian clock genes, have been identified in humans ([@B13]): *ARNTL* (aryl hydrocarbon receptor nuclear translocator like, also identify in brain and muscle as Arnt-like protein-1, BMAL1) ([@B14], [@B15]), *CLOCK* (clock circadian regulator) ([@B16]), *CRY1* (cryptochrome circadian clock 1), *CRY2* (cryptochrome circadian clock 2) ([@B17]), *PER1* (period circadian clock 1), *PER2* (period circadian clock 2), *PER3* (period circadian clock 3) ([@B18]--[@B20]), *CSNK1E* (casein kinase I epsilon) ([@B6], [@B21]), *NPAS2* (neuronal PAS domain protein 2) ([@B22], [@B23]), *NR1D1* (nuclear receptor subfamily 1 group D member 1 also called Rev-Erb alpha) ([@B24], [@B25]), *NR1D2* (nuclear receptor subfamily 1 group D member 2 also referred to Rev-Erb beta) ([@B26]), *RORA* (RAR related orphan receptor A) ([@B27]) and *TIMELESS* (timeless circadian clock) ([@B28], [@B29]).

In addition, there is a large amount of circadian genes from other clock-related pathways.

Ground-breaking works in the field of molecular cancer epidemiology have unveiled a large quantity of polymorphisms affecting the clock genes ([Table 1](#T1){ref-type="table"}). Studies on the relationship between clock genes polymorphisms and cancer susceptibility have established that variants of *ARNTL, CLOCK, CK1*ε*, CRY1-2, NPAS2*, and *PER1-3* are frequently associated to human reproductive tissues and pancreatic cancers ([@B1]).

###### 

Genetic association between circadian clock polymorphisms and different endocrine-related cancers.

  **Circadian gene**   **dbSNP ID**               **Cancer types**      **Phenotype**                                                    **References**
  -------------------- -------------------------- --------------------- ---------------------------------------------------------------- ----------------
  ARNTL                rs3816358                  Breast                Reduced risk                                                     ([@B30])
                       rs7950226                  Prostate              Increased risk                                                   ([@B31])
                       rs142435152                                      Risk associated                                                  ([@B4])
                       rs10732458                 Ovarian               Increased risk                                                   ([@B32])
                       rs117104877                                      Decreased risk                                                   
  CLOCK                rs11133373                 Prostate              Decreased risk                                                   ([@B31])
                       rs3805151                  Breast                Increased risk                                                   ([@B33])
                       rs10462028                                       Increased risk                                                   ([@B30])
  CRY1                 rs12315175                 Prostate              Increased risk                                                   ([@B34])
                       rs7297614 and rs1921126                          Fatal disease                                                    ([@B35])
                       rs10778534                                       Increased risk                                                   ([@B36])
                       rs1056560                  Breast                Heterozygous variant genotype decreased risk                     ([@B33])
  CRY2                 rs1401417                  Breast                Decreased risk                                                   ([@B33])
                       rs1401417                  Prostate              Increased risk                                                   ([@B37])
                       rs2292912                                        Decreased risk                                                   ([@B31])
  CSNK1E               rs135750                   Ovarian               Increased risk                                                   ([@B32])
                       rs1534891                  Prostate              Increased risk                                                   ([@B31])
  NPAS2                rs2305160                  Prostate              Decreased risk (lower insulin resistance)                        ([@B37])
                       rs895521 and rs1369481                           Decreased risk                                                   ([@B31])
                       rs17024926                                       Increased risk                                                   
                       rs23051560                 Breast                increased risk                                                   ([@B38])
  PER1                 rs885747                                         Heterozygous variant genotype decreased risk                     ([@B31])
                       rs2289591                                        Heterozygous variant genotype increased risk                     
  PER2                 rs7602358                  Prostate              Increased risk                                                   ([@B31])
                       rs934945                   Breast                Increased risk together with CLOCK homozygous variant genotype   ([@B33])
  PER3                 rs1012477                  Prostate              Increased risk                                                   ([@B31])
                       rs228697                                         Decreased risk                                                   ([@B36])
  RORA                 rs17191414                 Prostate and breast   Risk associated                                                  ([@B4])
                       rs1482057 and rs12914272   Breast                Risk associated                                                  ([@B39])
                       rs12913421                 Pancreatic            Decreased risk                                                   ([@B40])
  TIMELESS             rs2291738                  Breast                Decreased risk                                                   ([@B41])
                       rs7302060                  Breast                Decreased risk                                                   

Breast Cancer {#s3}
=============

Epidemiological studies have concluded an association between shift work and breast cancer risk ([@B42]--[@B44]). However, currently available experimental/epidemiological data are characterized by a great heterogeneity and some findings are in disagreement with previous observations about relationship between shift work and breast cancer risk ([@B45]).

A recent study in breast cancer showed that circadian genes CRY2 and *P*ER1-3 were down-regulated, while *CLOCK* and *TIMELESS* were over-expressed ([@B46]). This study confirms previous results where *PER1, PER2*, and *PER3* exhibited changes associated with the tumor suppressor activity ([@B47], [@B48]). In breast epithelial cells, an altered estrogen receptor signaling has been related to breast cancer and two circadian clock genes, *PER2* and *ARNTL*, both required for breast epithelial acinar morphogenesis *in vitro* ([@B49]).

Therefore, polymorphism studies in circadian clock-related genes and breast cancer, most of them have focused on the evaluation of the polymorphisms in core circadian genes, melatonin biosynthesis and signaling pathways. In this line, polymorphisms affecting *CLOCK* (rs3805151), *CRY1* (rs1056560), *CRY2* (rs1401417), and *PER2* (rs934945) ([@B33]) have been associated to breast cancer risk in a Chinese population. Concerning *CLOCK* gene, it was found that carrier subjects CT and CT+TT genotypes exhibited an increased risk of breast cancer in comparison to CC carriers. However, the GT genotype of the *CRY1* gene was the genetic variant with the lower risk of suffering cancer, as well as for those subjects carrying CC genotype of the *CRY2* gene having an even lower risk. Finally, simultaneous presence of *CLOCK* CC and *PER2* AA genotypes resulted in a higher risk of developing breast cancer ([@B33]).

An alternative study supporting the involvement of the *CLOCK* gene in the development of breast cancer came from a Bonn (Germany) population of shift workers. This case-control study analyzed the associations between breast cancer and polymorphisms in circadian clock genes (*ARTNL, CLOCK, CRY2, NPAS*, and *PER2*) and in genes of the melatonin pathway as well (*AANAT* and *MTNR1B*). In these workers with the rs8150 polymorphism from *AANAT* gene, as well as for the rs10462028 polymorphism from the CLOCK gene, was observed an increased frequency of breast cancer, while a lower risk was observed for the rs3816358 from ARNTL gene ([@B30]). Interaction analysis was performed in two-ways, detecting interactions between shift work and *CLOCK* gene. Therefore, interactions were found for shift work and *MTNR1B, ARNTL*, and *NPAS2* genes ([@B50]).

Additionally, a combined analysis of three genome wide associations studies (GWAS) was performed, including a total 285,984 SNPs (Single Nucleotid Polymorphisms) in an European population of 2.702 women with invasive breast cancer, in comparison to 5,726 subject controls. The most important association to breast cancer was found for genes implicated in the circadian clock ([@B51]). Monsees et al. conducted a study on 1,825 women finding common variants across 15 circadian system genes that were tested for association with breast cancer risk. The interaction study was designed in a subset of 1,318 women, showing interactions between genotype and rotating shift-work. *NPAS2* gene was strongly associated to the risk of developing breast cancer, and the rs23051560 variant was related with potential effects. The estimated risk value for the minor allele (A) was lower among women with \<2 years of shift-work compared to women with more than 2 years of shift-work ([@B38]).

In Europe, among a French population analyzed, 577 SNPs were found in 23 circadian clock genes associated with breast cancer risk in more than 1,000 cases and control subjects. *RORA* SNPs rs1482057 and rs12914272148 were also associated with breast cancer ([@B39]). Furthermore, a significant association has been shown between two SNPs in the *TIMELESS* gene (rs2291738 and rs7302060) ([@B33], [@B41]). In this study, C allele and CC genotype from rs7302060 polymorphism were associated with lower breast cancer risk. In rs2291738 polymorphism, GG genotype was related to decreased breast cancer risk.

On the other hand, limitations of the selected studies include the stratification of the populations according to different conditions among the different studies, such as shift work duration, menopausal status and expression levels of hormonal receptor in tumor tissues. Moreover, the polymorphism associations to breast cancer risk remain controversial, since some of these results were not able to be replicated in other populations or significance of associations is lost after adjusting for confounding factors. Furthermore, the described investigations included other limitations which will be further discussed in more detail.

Prostate Cancer {#s4}
===============

Prostate cancer exhibits the highest cancer prevalence in men, being the second cause of cancer-related deaths ([@B52]). Normal prostate cancer development is dependent on androgens levels. Circadian clock genes regulate androgen production ([@B53]), affecting prostate cancer evolution ([@B54]). On the other hand, a balanced regulation of the circadian clock genes might modulate and even suppress tumor growth by controlling DNA replication, repair mechanisms and cell proliferation ([@B55]). Although a limited number of epidemiologic studies have been realized, several circadian genes have been implicated in prostate cancer regulation: *ARNTL, CLOCK, CRY1-2, CSNK1e, MTNR1A* and *MTNR1B, NPAS2, NR1D1, PER1*-3, *RORA, RORB*, and *TIMELESS* ([@B4], [@B31], [@B56], [@B57]).

One of the first epidemiologic studies performed on prostate cancer and their associated SNPs, Chu et al. identified five polymorphisms in five circadian genes. This case-control study was conducted in a Chinese population with 187 cases and 242 control subjects ([@B37]). These polymorphisms encompassed *CRY2* rs1401417, *CSNK1E* rs1005473, *NPAS2* rs2305160, and *PER1* rs2585405. The C allele from *CRY2* presented an elevated prostate cancer risk compared to GG genotype carriers. Higher risk was found in men whom also sustained elevated insulin resistance (IR) compared to these with the GG genotype and lower IR. Moreover, the A allele from *NPAS2* polymorphism was associated with a reduced risk of developing prostate cancer in men with reduced IR when compared to the GG genotype carriers.

Zhu and colleagues also investigated the link between circadian gene with prostate tumors. The case-control study in a Caucasian men population included 1,308 cases and 1,266 control subjects. In this study was genotyped 41 variants in ten genes related with circadian clock ([@B31]). At least one polymorphism in nine clock circadian genes was significantly associated with prostate cancer risk. Specifically, it was found the variants rs7950226 in *ARNTL*, rs11133373 in *CLOCK*, rs12315175 in *CRY1*, rs2292912 in *CRY2*, rs1534891 in *CSNK1E*, rs1369481, rs895521, and rs17024926 in *NPAS2*, rs885747 and rs2289591 in *PER1*, rs7602358 in *PER2* and rs1012477 in *PER3*. They observed that the estimate risk for variants rs885747 and rs2289591 in *PER1*, rs1012477 in *PER3*, and rs11133373 in *CLOCK* significantly changed depending on disease aggressiveness.

Lin et al. carried out studies in prostate cancer using two populations, from Seattle and Sweden, respectively) ([@B36]). They genotyped 937 polymorphisms corresponding to 156 genes in 1,309 men with prostate cancer in a Seattle cohort. They identified 22 variants associated to prostate cancer-specific mortality (PCSM), and validated them afterward in a Swedish cohort (2,875 patients. In the Swedish cohort, five polymorphisms out of the 22 SNPs identified in the Seattle cohort, were found to be significantly associated with PCSM, with a statistical significance variant in the CRY1 gene (rs10778534). The study also identified another variant in the Seattle cohort, rs228697 in *PER3*, associated with PCSM, which was not further tested in the Swedish cohort due to genotyping drawbacks.

Another study evaluating the association between mortality in prostate cancer and circadian clock-related genes was carried out by Markt et al. ([@B35]). Authors tested 96 variants in 12 circadian-related genes using 3 patient cohorts (24, 40, and 105 cases/respectively). It was also analyzed the association with lower levels of melatonin (measured by 6-sulfatoxymelatonin). This study showed no variants significantly associated with overall risk of prostate cancer, however in all cohorts was observed that variation in the *CRY1* gene was associated with mortality in prostate cancer This study of individual cohorts revealed that two polymorphisms from *CRY1*, rs7297614, and rs1921126 were associated to increased mortality in 2 out 3 prostate cancer cohorts, and a similar association was proved for rs12315175 in the *CRY1* gene in a single cohort. Finally, their analysis of the 6-sulfatoxymelatonin levels showed that patients with metabolite levels lower than the median had an increased risk of advanced disease, where polymorphisms in *CSNK1E, NPAS2, PER3*, and *TIMELESS* were associated to changes in these 6-sulfatoxymelatonin production. Future investigations should be designed including a large population compared to the one used in this study, and similar clinicopathological factors as well to ensure statistical power and allow for results comparisons.

Recently, Mocellin et al. performed an analysis using adaptive rank truncated product (ARTP)-based gene and pathway analysis to discern the relevance of the variation in circadian clock genes and cancer susceptibility ([@B4]). In this analysis using previously published dataset of prostate cancer ([@B58]), they found a highly significant association between genetic variation of circadian pathway and susceptibility to prostate cancer. This result was founded on data regarding 17 SNPs located in seven genes, with the most significant SNP rs142435152 from *ARNTL* gene. Their analysis of subgroups revealed that the risk of suffering aggressive prostate cancer was also highly associated with circadian pathway variation. This finding was based on 28 SNPs located in seven genes, where the most significant gene was *RORA* with the rs17191414 SNP.

Ovarian Cancer {#s5}
==============

Ovaries express circadian genes at high levels to regulate hormonal levels during reproductive cycles, and the disruption of this expression is associated to different risk factors for ovarian cancer (e.g., endometriosis).

An association between nightshift work and elevated risk of invasive and borderline ovarian cancers have been described in women aged over 50 years ([@B59]). A GWAS and a replication study for epithelial ovarian cancer (EOC) analyzed variants of several circadian genes (ARNTL*, CRY2, CSNK1E, NPAS2, PER3, REV1*, and *TIMELESS*) and two transcription factors (*KLF10* and *SENP3*) ([@B32]). The study examined 3,761 EOC patients and 2,722 control subjects. A replication stage was evaluated with \~44,000 subjects with European ancestry. This study indicates that circadian clock genes could act in the development of EOC, particularly *ARNTL* rs10732458, *CSNK1E* rs135750, *SENP3* (rs6608), and *REV1* rs3792152 variants. SNPs in K*LF10* (rs2513928, rs2511703, rs3191333, and rs2513927) were also associated with serious risk of EOC. Interestingly, the most significant association was the rs117104877 variant in *ARNTL*. Ablation of *ARNTL* in mice causes ovary tumors via reduction of p53 expression ([@B60]) and dysregulation response to anti-cancer drugs ([@B61]). In addition, lower *ARNTL* and *CRY1* expression levels in EOC cells were found after comparison to normal ovarian tissue ([@B62]).

Nevertheless, an alternative study has evaluated polymorphism association in nine circadian clock-related genes (*ARNTL, CKIE, CLOCK, CRY1-2, CSNKIE, NPAS2*, and *PER1-3*), but however, it did fail finding any association between genes of the circadian rhythm pathway and ovarian cancer ([@B63]).

Pancreatic and Thyroid Cancer {#s6}
=============================

Pancreatic cancer is a major cause of cancer mortality in western countries population. Several studies have shown disruption of circadian genes expression associated to pancreatic cancer ([@B64]--[@B68]). However, only one study was able to show an association between circadian genes and pancreatic cancer. It found association between the SNP rs12913421 in *RORA* gene and pancreatic cancer, but the significance disappeared after correcting for multiple comparisons ([@B40]). Nevertheless, this study was not specifically designed to evaluate association between polymorphisms in genes of the circadian rhythm pathway and pancreatic cancer. Additional studies of polymorphisms in the circadian pathway are urgently needed, with systematical studies of fine mapping and sufficient sample size.

On the other hand, the disruption of circadian clock genes has been associated to a higher risk of thyroid tumors ([@B69], [@B70]).

Despite this result, no studies have examined the association between polymorphism in circadian genes and thyroid cancer.

Discussion and Future Perspectives {#s7}
==================================

A better understanding of molecular mechanisms in endocrine-related cancers may facilitate early diagnosis, prognosis and therapies development. Therefore, studies should be improved in several aspects. The reviewed studies about the association of circadian gene polymorphisms to cancer risk have been only conducted in European an East Asian population. Additional studies should be implemented in other ethnic groups to validate epidemiological data.

On the other hand, selection of genetic polymorphisms and experimental and statistical analysis approaches were different among cancer studies and thus, they were not comparable in most cases. These differences might consequently influence the associations found between germline variants and cancer risk.

In future studies, functional implications of the circadian pathway polymorphisms associated to endocrine cancer should be also evaluated. Polymorphisms localized in the 3′UTR could regulate gene transcription. However, the majority of the studied polymorphisms are located in intron regions, thus it is unknown how polymorphisms modulate their functions resulting in a higher or lower cancer risk.

Our review reports that the polymorphisms of some circadian genes are related to cancers of reproductive tissues, where some genes are associated and implicated in three types of tumors (*ARNTL* gene in prostate, breast and ovary), two types of tumors (*CLOCK, CRY1, CRY2, NPAS2*, and *PER2* genes in breast and prostate and *CSNK1E* gene in prostate and ovary) or alternatively they are more specific to one type of cancer (*PER1* and *PER3* genes in prostate and *TIMELESS* gene in breast). Other circadian genes are associated and implicated by several endocrine-related cancers (*RORA* gen in prostate, breast and pancreas).

The current findings suggest that some genes must be involved in the predisposition to cancer development of reproductive tissues, other genes must be specific to a type of cancer, and other genes should affect tissues modulated by endocrine hormones. The effect of these genes is probably showed up at the hormone pathways level, as in the *CLOCK* gene. The activity of the *CLOCK* gen product regulates estrogenic and androgenic hormonal pathways ([@B71], [@B72]). This could be related to the fact that polymorphisms of this gene alter the regulation of these pathways and produce an uncontrolled proliferation of prostate, breast and ovarian tissue cells.

We reckon that a screening of polymorphisms related with the circadian clock could provide valuable information regarding predisposition of suffering a particular type of cancer, thus facilitating its prognosis. When cancer is already present, malignancy intervention strategies could be immediately applied due to earlier detection.

Concluding Remarks {#s8}
==================

Compelling evidence supports the notion that loss of circadian homeostasis promotes endocrine cancer development. Genetic component is a key factor that contributes to dysregulation of the circadian clock. Polymorphisms of circadian clock genes are associated to the risk of suffering an endocrine cancer and poor performance to of therapies with anticancer treatments, particularly, these related to reproductive tissues. The findings detailed in this review indicate an exciting research line in order to investigate clock-controlled tumor suppression, also in other organs regulated by circadian rhythms that need high levels of cell proliferation to support their functions, such as thyroid or pancreas.
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